Solix Technologies and Symbiosis Medical College for Women have launched a Center of Excellence to accelerate drug discovery using artificial intelligence, computational modeling, and clinical research. The partnership, announced at TAL HealthFest 2026, aims to address two urgent healthcare challenges: Alzheimer's disease and antimicrobial-resistant pathogens .

What Problem Are They Trying to Solve?

Drug discovery today faces a stubborn problem. The process is slow, expensive, and risky. Researchers spend years testing compounds in the lab, only to see most fail before they ever reach human trials. The current approach involves high pre-clinical attrition rates, extended development timelines, and escalating research and development costs . By integrating artificial intelligence with traditional laboratory work, the new center hopes to reduce those failures earlier and move promising candidates forward faster.

The collaboration brings together two complementary strengths: Solix's 25 years of expertise in data management and enterprise artificial intelligence, combined with Symbiosis Medical College for Women's clinical, translational, and biomedical research capabilities . This pairing of technology and medical expertise represents a shift in how drug discovery is being approached.

How Will the Center Actually Work?

• Computational Intelligence: The center will use artificial intelligence-driven in-silico modeling, which means running drug simulations on computers before testing anything in living organisms. This allows researchers to screen thousands of potential compounds virtually.
• Molecular Validation: Promising candidates identified by AI will be tested in laboratory settings to confirm they behave as predicted and don't have unexpected side effects.
• In-Vivo Translational Research: The most promising compounds will then move to testing in living systems, bridging the gap between computer predictions and real-world biology.

The center will initially focus on two areas: Alzheimer's disease and priority antimicrobial-resistant pathogens . These represent two of the most pressing global health challenges. Alzheimer's affects millions worldwide with limited treatment options, while antimicrobial resistance threatens to make common infections untreatable.

"At Solix, we believe the future of drug discovery lies in intelligent data harmonization and AI-driven translational science. By partnering with Symbiosis Medical College for Women, we are creating a platform that integrates computational intelligence with molecular and clinical validation. This Center of Excellence will help accelerate therapeutic breakthroughs while reducing pre-clinical risk," said Sai Gundavelli, Founder and CEO of Solix Technologies.

Sai Gundavelli, Founder and CEO, Solix Technologies

Why Does This Partnership Matter for Healthcare?

The collaboration addresses a critical gap in modern drug development. As researchers generate increasingly complex data from in-silico, in-vitro, and in-vivo experiments, they struggle to connect insights across these different domains. Solix's technology uses semantic layering and neuro-symbolic artificial intelligence, which essentially means the system can understand relationships between different types of data and reason about them in ways that mimic human thinking . This helps researchers spot patterns they might otherwise miss.

The center will also serve practical functions beyond research. It will enable industry collaboration and contract research organization services, support intellectual property generation, and train undergraduate, postgraduate, and doctoral students in translational drug development . In other words, it's not just a research facility; it's designed to become an ecosystem where academic training, industry partnerships, and innovation happen together.

"Having doctors' insights is vital for drug repurposing and new drug discovery. This collaboration between a medical college and a technology company is a powerful example of transdisciplinary synergy in action," noted Prof V K Sashindran, Dean and Professor of Medicine at Symbiosis Medical College for Women.

Prof V K Sashindran, Dean and Professor of Medicine, Symbiosis Medical College for Women

How Does This Fit Into Broader Healthcare Goals?

The initiative aligns with national missions supported by India's Department of Biotechnology, Indian Council of Medical Research, Department of Science and Technology, and antimicrobial resistance action plans . This means the center isn't operating in isolation; it's part of a larger push toward scientific self-reliance and healthcare innovation at the national level.

The focus on drug repurposing is particularly noteworthy. Rather than only developing entirely new drugs, the center will also identify approved and investigational drugs that could be repurposed for new conditions. This approach can be faster and cheaper than starting from scratch, since safety profiles for these drugs are already known.

As artificial intelligence continues to reshape healthcare and pharmaceutical research, partnerships like this one signal a shift toward more integrated, data-driven approaches to solving some of medicine's toughest problems. The real test will come when the center's AI-accelerated discoveries move into clinical trials and eventually reach patients who need them.